Tana Cooper, DO
Family Medicine · Biloxi, MSNPI 1174730519
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,675 of the $25,277 with a category attached, or 85.7%. AstraZeneca accounts for 80.8% of it on its own, with 25 other manufacturers making up the rest. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $136.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- Myriad Women's Health, Inc.$2K
- Renalytix AI, Inc.$543
- Lilly USA, LLC$346
- GSK$270
- Amgen$242
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$21,67586%
- Travel & lodging$2651%
- Food & beverage$3,33713%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $20,435 |
| Myriad Women's Health, Inc. | 4 | $2,375 |
| Renalytix AI, Inc. | 23 | $543 |
| Lilly USA, LLC | 23 | $346 |
| GSK | 23 | $270 |
| Amgen | 10 | $242 |
| Averitas Pharma Inc. | 4 | $199 |
| Bayer | 6 | $120 |
| Silk Road Medical, Inc. | 1 | $120 |
| Novo Nordisk | 7 | $101 |
| GRT US Holding, Inc. | 1 | $87 |
| Biohaven Pharmaceuticals, Inc. | 3 | $76 |
| Merck | 4 | $65 |
| Pfizer | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Exact Sciences | 2 | $31 |
| AbbVie | 2 | $30 |
| Genentech USA, Inc. | 2 | $28 |
| Medtronic | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,277 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 135 | $128,767 |
| EliquisApixaban | 257 | $60,560 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $60,148 |
| JardianceEmpagliflozin | 73 | $53,494 |
| MounjaroTirzepatide | 38 | $38,436 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $37,305 |
| TrulicityDulaglutide | 27 | $31,122 |
| OzempicSemaglutide | 18 | $27,883 |
| JanuviaSitagliptin Phosphate | 72 | $27,822 |
| LinzessLinaclotide | 17 | $22,668 |
| MyrbetriqMirabegron | 78 | $20,946 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $11,271 |
| EntrestoSacubitril/Valsartan | 43 | $7,204 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $6,982 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 143 | $5,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $20,435 | $166,072171 claims |
| Lilly USA, LLCMounjaro, Trulicity | $346 | $69,55865 claims |
| PfizerEliquis | $38 | $60,560257 claims |
| GSKTrelegy Ellipta | $270 | $60,14853 claims |
| Boehringer IngelheimJardiance, Tradjenta | $14 | $57,582104 claims |
| MerckJanuvia, Janumet | $65 | $39,09389 claims |
| Novo NordiskOzempic | $101 | $27,88318 claims |
| AbbVieLinzess | $30 | $22,66817 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $20,94678 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Biloxi
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
- Andrea PhillipsJackson$96K
- Kristi TrimmRidgeland$34K
- Delora DenneyPicayune$24K
- Randall HulingOlive Branch$23K
- Timothy QuinnRidgeland$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.